Medanta Q3 FY25 results: Revenue up 12.8% YoY to Rs 9,434 crore, net profit rises 15.6% YoY

Medanta continues to expand its presence in key markets, with the company adding a 110-bed super-specialty hospital in Ranchi under a lease agreement. The new facility will enhance high-end tertiary and quaternary care services and strengthen Medanta’s presence in Eastern India.

Global Health Limited (Medanta), one of India’s leading multi-specialty hospital chains, has reported a strong financial performance for the quarter ended December 31, 2024 (Q3 FY25), with 12.8% year-on-year (YoY) growth in revenue from operations.

Key financial highlights (Q3 FY25 vs. Q3 FY24)

Advertisement

  • Revenue from operations: ₹943.4 crore, up 12.8% from ₹836.5 crore in Q3 FY24.
  • Total income: ₹959.5 crore, an increase from ₹854.5 crore in the same quarter last year.
  • EBITDA: ₹253.8 crore, compared to ₹238.0 crore in Q3 FY24.
  • Profit after tax (PAT): ₹142.9 crore, up 15.6% from ₹123.5 crore in Q3 FY24.
  • EBITDA margin: 26.9%, showing stable operational efficiency.
  • Earnings per share (EPS): ₹5.32, compared to ₹4.61 in Q3 FY24.

Nine-month performance (April–December 2024 vs. April–December 2023)

  • Revenue from operations: ₹2,761.1 crore, up 11.9% from ₹2,466.5 crore in the same period last year.
  • Profit after tax (PAT): ₹379.9 crore, reflecting a 8.3% YoY increase.
  • Total comprehensive income: ₹381.5 crore, up from ₹349.8 crore last year.

Medanta continues to expand its presence in key markets, with the company adding a 110-bed super-specialty hospital in Ranchi under a lease agreement. The new facility will enhance high-end tertiary and quaternary care services and strengthen Medanta’s presence in Eastern India.

Additionally, Medanta has signed a definitive agreement to operate and manage a 750-bed hospital in Pitampura, New Delhi, further strengthening its position in North India.

With a focus on expansion, operational efficiency, and high-end specialty care, Medanta remains committed to scaling its operations while maintaining profitability. The company’s EBITDA margins and revenue growth trajectory indicate sustained demand for quality healthcare services across India.